Get the Stockscreener App
23.61
4.95%
-1.23
Syndax Pharmaceuticals Inc stock is traded at $23.61, with a volume of 2.10M.
It is down -4.95% in the last 24 hours and up +34.30% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$24.84
Open:
$24.79
24h Volume:
2.10M
Relative Volume:
1.12
Market Cap:
$2.09B
Revenue:
$217.42M
Net Income/Loss:
$-243.25M
P/E Ratio:
-8.4466
EPS:
-2.7952
Net Cash Flow:
$-278.35M
1W Performance:
+8.20%
1M Performance:
+34.30%
6M Performance:
+12.43%
1Y Performance:
+140.43%
1-Day Range:
$23.01
$24.79
1-Week Range:
$21.24
$25.24
52-Week Range:
$9.03
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
23.61 | 2.09B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily
Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria
Syndax CEO Michael Metzger sells $784,776 in company stock - Investing.com
Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan - Stock Titan
Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing - Moomoo
Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares - MarketBeat
Syndax CEO Michael Metzger sells $784,776 in company stock By Investing.com - Investing.com Canada
Form 144 Syndax Pharmaceuticals For: 8 July By Investing.com - Investing.com Nigeria
SNDX insider files to sell 32,375 shares (NASDAQ: SNDX) - Stock Titan
Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next - simplywall.st
Syndax Pharmaceuticals holds steady as investors await a fresh catalyst - AD HOC NEWS
SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In? - Sahm
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals (NASDAQ:SNDX) Draws Fresh Market Attention - Kalkine Media
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates? - Insider Monkey
Purchase/sale of business (net) of Syndax Pharmaceuticals Inc – SWB:1T3 - TradingView
Price to sales forward of Syndax Pharmaceuticals Inc – MUN:1T3 - TradingView
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Does Syndax Pharmaceuticals’ (SNDX) Russell Value Index Exit Quietly Recast Its Liquidity And Risk Narrative? - simplywall.st
Enterprise value to revenue forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Trading the Move, Not the Narrative: (SNDX) Edition - Stock Traders Daily
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Price to earnings forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Price to earnings forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Syndax Pharmaceuticals (SNDX) Surges 7.6% as Momentum Builds Past Key SupportButterfly Setup - dars.gov.et
Enterprise value to revenue forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Price to book forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Price to sales forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Price to book forward of Syndax Pharmaceuticals Inc – MUN:1T3 - TradingView
Syndax Pharmaceuticals stock jumps 7.57% as Syndax applauds Dana-Farber's Dr. Armstrong award - Traders Union
Syndax Pharmaceuticals Inc Actuals & Estimates (DUS:1T3) - TradingView
SNDX Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
1T3 Forecast — Price Target — Prediction for 2027 - TradingView
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal - AOL.com
Syndax Pharmaceuticals (SNDX) Stock Could Be 51.9% Undervalued After SAVE Trial Data - Sahm
Syndax Pharmaceuticals Inc (SNDX) Institutional Confidence - TradingKey
Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Syndax Pharmaceuticals StockLong-term cancer strategy under investor scrutiny - AD HOC NEWS
Is Strong SAVE Trial Data Altering The Investment Case For Syndax Pharmaceuticals (SNDX)? - Sahm
Elmind Capital LP Purchases New Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Catalio Capital Management LP - MarketBeat
Eversept Partners LP Decreases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Syndax Pharmaceuticals Inc - TradingKey
Apis Capital Advisors LLC Acquires 86,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):